Search results for "Prostatic neoplasms"

showing 10 items of 284 documents

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

2017

Abstract: Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derived extracellular vesicles such as exosomes. Exosomes have been shown to act as…

0301 basic medicinePCA3MaleCancer ResearchBiomarker; Exosome; Liquid biopsies; MiRNAs; Prostate cancerBioinformaticsExosomesExosome03 medical and health sciencesProstate cancer0302 clinical medicineProstateLiquid biopsiemicroRNABiomarkers TumorMedicineHumansLiquid biopsyProstate cancerbusiness.industryLiquid BiopsyCancerProstatic NeoplasmsGeneral MedicineBiomarkermedicine.diseaseMicrovesiclesExosomeMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchHuman medicinebusinessMiRNA
researchProduct

The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.

2018

Prostate-specific membrane antigen (PSMA) is a transmembrane protein with significantly increased expression in the cells and metastases of prostate carcinoma (CaP). PSMA-expression correlates with higher serum levels of prostate-specific antigen (PSA) and a higher Gleason score (GS). This finding has led to the development of novel imaging modalities such as 68Ga-/18F-labeled PSMA positron emission tomography/computed tomography (PET/CT) and positron emission tomography/magnetic resonance imaging (PET/MRI). This article reviews the literature pertaining to various new imaging technologies for the management of CaP. PSMA positron emission tomography/computed tomography appears to be an exce…

MaleUrology030232 urology & nephrologyComputed tomographyGallium Radioisotopesurologic and male genital diseasesMultimodal ImagingManagement of prostate cancer03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographymedicineOrganometallic CompoundsHumansGallium IsotopesMembrane antigenSalvage TherapyPET-CTMembrane Glycoproteinsmedicine.diagnostic_testbusiness.industry68ga psmaProstatic NeoplasmsMagnetic resonance imagingProstate carcinomaProstate-Specific AntigenMagnetic Resonance ImagingPositron emission tomography030220 oncology & carcinogenesisPositron-Emission TomographyNeoplasm Recurrence LocalRadiopharmaceuticalsbusinessNuclear medicineUrology
researchProduct

Involvement of Bax and Bcl-2 in induction of apoptosis by essential oils of three Lebanese Salvia species in human prostate cancer cells

2018

Prostate cancer is one of the most common forms of cancer in men, and research to find more effective and less toxic drugs has become necessary. In the frame of our ongoing program on traditionally used Salvia species from the Mediterranean Area, here we report the biological activities of Salvia aurea, S. judaica and S. viscosa essential oils against human prostate cancer cells (DU-145). The cell viability was measured by 3(4,5-dimethyl-thiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) test and lactate dehydrogenase (LDH) release was used to quantify necrosis cell death. Genomic DNA, caspase-3 activity, expression of cleaved caspase-9, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X (Ba…

Male0301 basic medicineSalvia miltiorrhiza<i>Salvia</i>; essential oil; prostate cancer; apoptosis; reactive oxygen specieslcsh:ChemistryProstate cancer0302 clinical medicineSalvialcsh:QH301-705.5Spectroscopybcl-2-Associated X Proteinreactive oxygen speciesCamphanesapoptosisGeneral Medicineprostate cancerComputer Science ApplicationsGene Expression Regulation NeoplasticProto-Oncogene Proteins c-bcl-2030220 oncology & carcinogenesisApoptosis Essential oil Prostate cancer Reactive oxygen species SalviaProgrammed cell deathSalvia; apoptosis; essential oil; prostate cancer; reactive oxygen speciesPanax notoginsengDNA FragmentationBiologyArticleCatalysisessential oilInorganic Chemistry03 medical and health sciencesBcl-2-associated X proteinCell Line TumorOils VolatilemedicineHumansViability assayPhysical and Theoretical ChemistryMolecular BiologyCell ProliferationCell growthOrganic ChemistryProstatic NeoplasmsCancerSettore CHIM/06 - Chimica Organicamedicine.diseaseapoptosi030104 developmental biologylcsh:Biology (General)lcsh:QD1-999ApoptosisCancer cellCancer researchbiology.proteinDrugs Chinese Herbal
researchProduct

Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultra…

2018

Active surveillance has gained acceptance as an alternative to definitive therapy in many men with prostate cancer. Confirmatory biopsies to assess the appropriateness of active surveillance are routinely performed and negative biopsies are regarded as a favorable prognostic indicator. We sought to determine the prognostic implications of negative multiparametric magnetic resonance imaging-transrectal ultrasound guided fusion biopsy consisting of extended sextant, systematic biopsy plus multiparametric magnetic resonance imaging guided targeted biopsy of suspicious lesions on magnetic resonance imaging.All patients referred with Gleason Grade Group 1 or 2 prostate cancer based on systematic…

Image-Guided BiopsyMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrology03 medical and health sciencesProstate cancer0302 clinical medicineBiopsyMedicineHumansProspective StudiesProspective cohort studyWatchful WaitingMultiparametric Magnetic Resonance ImagingUltrasonography InterventionalAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsMagnetic resonance imagingRetrospective cohort studyMiddle Agedmedicine.diseasePrognosisMagnetic Resonance ImagingDisease ProgressionRadiologyNeoplasm GradingbusinessImage-Guided BiopsyWatchful waitingThe Journal of urology
researchProduct

Alpha emitting nuclides in nuclear medicine theranostics.

2021

Theranostic applications with radio-isotopes currently are rapidly progressing and expand nuclear medicine application in clinical routine. Alpha emitting isotopes, in particular, have long been hypothesized to achieve relevant advances for the treatment of malignancies. Here, an overview of their properties and the knowledge of radiobiology is reviewed in view of clinical translation. Clinical evidence of radiopharmaceuticals based on alpha emitters is summarized with a focus on recent developments for treatment of metastasized castration resistant prostate cancer.Theranostische Anwendungen mit Radioisotopen machen derzeit rasche Fortschritte und erweitern den Einsatz der Nuklearmedizin in…

MaleRadiobiologybusiness.industryProstatic NeoplasmsGeneral MedicineCastration resistantClinical routineTheranostic NanomedicineClinical evidenceMedicineHumansRadiology Nuclear Medicine and imagingNuclideNuclear MedicinePrecision MedicineRadiopharmaceuticalsNuclear medicinebusinessRadionuclide ImagingNuklearmedizin. Nuclear medicine
researchProduct

Nitrosoureas Modes of Action and Perspectives in the Use of Hormone Receptor Affine Carrier Molecules

1989

Mechanisms of DNA adduct formation by antineoplastic 2-chloroethyl-N-nitrosoureas (CNUs) and of DNA damage induced by these compounds are discussed. CNUs are alkylating agents that form DNA-DNA cross-links as well as 2-chloroethylated and 2-hydroxyethylated adducts, the N-7-position of guanine being the predominantly alkylated site. A close correlation exists between the potential of a given compound to induce DNA-DNA cross-links and its antineoplastic effectiveness. However, levels of DNA-DNA cross-linking in bone marrow and extent of myelosuppression as measured in rodents are also closely correlated. The design of new cross-linking analogues capable of directing the antineoplastically re…

MaleNeoplasms Hormone-DependentDNA damageGuaninemedicine.medical_treatmentAntineoplastic AgentsReceptors Cell SurfaceNitrosourea CompoundsAdductStructure-Activity Relationshipchemistry.chemical_compoundBone MarrowmedicineAnimalsHumansRadiology Nuclear Medicine and imagingDrug Carriersbusiness.industryMammary Neoplasms ExperimentalProstatic NeoplasmsEstrogensHematologyGeneral MedicineSteroid hormoneOncologyMechanism of actionBiochemistrychemistryHormone receptormedicine.symptombusinessDNAHormoneActa Oncologica
researchProduct

Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo.

1999

Phenylbutyrate (PB) is a potent differentiating agent and currently under investigation for the treatment of prostate cancer (CaP) and other malignancies. We have studied the impact of PB in vitro and in vivo on differentiation, proliferation and apoptosis in the LNCaP and LuCaP 23.1 prostate cancer xenograft models. In vitro we found that i) PB increased PSA secretion/cell, ii) inhibited cell proliferation in a time- and dose-dependent manner resulting in a cell cycle arrest in G1-phase and iii) induced apoptosis at concentrations of 2.5 mM after 3 days of treatment. In PB treated animals tumor growth stabilized or regressed. Combination of castration and PB treatment had a synergistic ant…

MaleCancer Researchmedicine.medical_specialtyProgrammed cell deathTransplantation HeterologousMice NudeAntineoplastic AgentsApoptosisBiologyPhenylbutyrateMiceProstate cancerIn vivoInternal medicineLNCaPTumor Cells CulturedmedicineAnimalsHumansMice Inbred BALB CCell growthCell CycleProstatic NeoplasmsCancerCell Differentiationmedicine.diseasePhenylbutyratesDisease Models AnimalEndocrinologyOncologyCancer cellAndrogensCancer researchCell DivisionNeoplasm TransplantationInternational Journal of Oncology
researchProduct

Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian M…

2020

Abstract Background We investigated, in a real-life setting, the prognostic relevance of previous primary treatment (radical prostatectomy [RP] or external beam radiotherapy [EBRT]) on overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Materials and Methods In the present multicenter retrospective study, we enrolled 275 consecutive patients. The demographic and clinical data and mCRPC characteristics were recorded and evaluated at baseline and at the end of treatment or progression. 223Ra was administered according to the current label authorization until disease progression or unacceptable toxicity. We divided the who…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentoverall survivalBrachytherapy030232 urology & nephrologyUrology223-ra03 medical and health sciencesProstate cancer0302 clinical medicineAblative casemedicineHumansExternal beam radiotherapyradiotherapyAgedRetrospective StudiesAged 80 and overProstatectomyRadioisotopesbusiness.industryProstatectomyRetrospective cohort studymCRPCMiddle AgedProtective Factorsmedicine.diseasePrognosisCombined Modality TherapyRadiation therapySurvival RateProstatic Neoplasms Castration-ResistantOncologyMulticenter study223-ra; mCRPC; prostatectomy; radiotherapy; overall survivalItaly030220 oncology & carcinogenesisCohortDisease ProgressionbusinessSettore SECS-S/01Follow-Up StudiesRadium
researchProduct

Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral res…

2008

Abstract Background The kinetics and reproducibility of serum prostate-specific antigen (PSA) following extended multisite biopsies are unknown. The aim of this study was to examine the kinetics of hematogenous leakage of PSA molecules by comparing the postintervention PSA manner among extended biopsies, transurethral resection of the prostate (TURP) and biopsy plus TURP. Methods Total and free PSA values were examined before and sequentially after intervention (at 1 hour, 24 hours, 2 days, 14 days, and 28 days), in patients who underwent 14-core prostate biopsy (Biopsy, n = 53), TURP (TURP, n = 21), or prostate biopsy plus TURP (Biopsy+TURP, n = 18). Results Ten patients in the Biopsy grou…

MaleNephrologymedicine.medical_specialtyProstate biopsyBiopsyUrologymedicine.medical_treatmentUrologyurologic and male genital diseasesProstate cancerProstateInternal medicineBiopsymedicineHumansProspective StudiesAgedTransurethral resection of the prostateAged 80 and overmedicine.diagnostic_testGenitourinary systembusiness.industryProstateTransurethral Resection of ProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgeryProstate-specific antigenmedicine.anatomical_structureOncologybusinessUrologic Oncology: Seminars and Original Investigations
researchProduct

Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis.

2022

Abstract Objectives Prostate cancer (PCa) represents the second most common solid cancer in men worldwide. In the last decades, the prostate health index (PHI) emerged as a reliable biomarker for detecting PCa and differentiating between non-aggressive and aggressive forms. However, before introducing it in clinical practice, more evidence is required. Thus, we performed a systematic review and meta-analysis for assessing the diagnostic performance of PHI for PCa and for detecting clinically significant PCa (csPCa). Methods Relevant publications were identified by a systematic literature search on PubMed and Web of Science from inception to January 11, 2022. Results Sixty studies, including…

MalePCaprostate tumordiagnosisscreeningBiopsyBiochemistry (medical)Clinical BiochemistryProstateProstatic NeoplasmsGeneral MedicineProstate-Specific AntigenSettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicaclinically significant prostate cancer (csPCa)biomarkerHumansprostate health index (PHI)BiomarkersClinical chemistry and laboratory medicineReferences
researchProduct